Search | Clinical Trials Finder

Conditions: Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis
Interventions: MMB; Drug
Lead sponsor: Sierra Oncology LLC - a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more

Conditions: Myocardial Infarction, Anemia
Interventions: Packed Red Blood Cell Transfusion; Procedure
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Durham, North Carolina

Conditions: Myelodysplastic Syndromes
Interventions: Luspatercept, Epoetin alfa; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 25
States / cities: Berkeley, California • San Diego, California • Whittier, California + 22 more

Conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Interventions: Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab, Supportive care measures; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: Open Posterior Thoracolumbar Spinal Fusion Procedure
Interventions: Tranexamic Acid Injectable Product (1000 mg intravenous bolus), Vitamin C 250 MG Oral Tablet, Tranexamic Acid 650Mg Tablet; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Etavopivat tablets; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: Cerritos, California • Los Angeles, California • Oakland, California + 9 more

Conditions: Anemia, Sickle Cell
Interventions: Monthly blood transfusion regimen, Usual care; Procedure · Behavioral
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 21 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 14
States / cities: Oakland, California • Washington D.C., District of Columbia • Hollywood, Florida + 10 more

Conditions: Covid19
Interventions: Convalescent Plasma, Standard of Care; Drug · Other
Lead sponsor: Larkin Community Hospital; Other
Eligibility: 40 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: C.Surgical Procedure; Cardiac
Interventions: Acute normovolemic hemodilution, Standard care; Procedure
Lead sponsor: Università Vita-Salute San Raffaele; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Charlottesville, Virginia

Conditions: Scoliosis, Kyphosis, Lordosis, Spondylitis, Spinal Stenosis
Interventions: Epsilon-Aminocaproic Acid (EACA), Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiac Surgery, Erythrocyte Transfusion
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Durham, North Carolina

Conditions: Tranexamic Acid, Cancer, Major Surgery
Interventions: Tranexamic Acid, Placebo; Drug · Other
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Thalassemia
Interventions: Busulfan, Fludarabine, Campath 1H, Cyclophosphamide, MESNA; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 64 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Iron, Abnormal Blood Level, Other Abnormal Blood Chemistry
Interventions: Fresh transfusion, Old transfusion; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Resectable Pancreatic Carcinoma
Interventions: Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL), Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL), Computed Tomography, X-Ray Imaging, Biospecimen Collection, Survey Administration, Pancreatectomy; Biological · Procedure · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Medication Administered in Error, Antipsychotics and Neuroleptics Toxicity
Interventions: Simulation, Online educational training; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Trauma
Interventions: Thromboelastometry guided transfusion; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 14 Years to 100 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cardiovascular Disease
Interventions: Hemolink (hemoglobin raffimer IV solution); Drug
Lead sponsor: Hemosol; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: San Francisco, California • Stanford, California • Sarasota, Florida + 14 more

Conditions: Anemia, Cooley's, Beta-Thalassemia, Hematologic Diseases, Thalassemia, Osteoporosis, Iron Overload, Hypertension, Pulmonary
Interventions: Deferoxamine, Deferiprone, Arginine, Sildenafil, Decitabine; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 1 Year to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 4
States / cities: Oakland, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Preterm Birth, Blood Transfusion Complication, Hypothermia
Interventions: Ranger blood warmer (3M Healthcare, Oakdale, Minnesota); Device
Lead sponsor: University of South Carolina; Other
Eligibility: 24 Weeks to 32 Weeks
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma
Interventions: ADR-529, Topotecan, G-CSF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions: Iron Sucrose; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Leukemia
Interventions: Azacitidine (AZA) Days 1 - 3, Decitabine (DAC), Best Supportive Care (BSC), Azacitidine (AZA) Days 1 - 5; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 6
States / cities: Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Anemia of Prematurity
Interventions: feed during blood transfusion; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 25 Weeks to 38 Weeks
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease - Pilot Intervention Study

Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.

Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery

Impact of Blood Storage Duration on Physiologic Measures

TXA Study in Major Oncologic Surgery

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

Fresh Versus Old Red Blood Cells for Transfusion

Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

Novel Application of Simulation for Providers to Overcome Decisional Gaps in High-risk Prescribing

Rotational Thromboelastometry Activated Transfusion In Trauma Trial

Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Blood Warming in Preterm Infants to Decrease Hypothermia

New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants